Get the Stockscreener App
0.6001
5.00%
-0.0316
Lakewood Amedex Biotherapeutics Inc stock is traded at $0.6001, with a volume of 119.23K.
It is down -5.00% in the last 24 hours and down -72.35% over the past month.
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
See More
Previous Close:
$0.6317
Open:
$0.6
24h Volume:
119.23K
Relative Volume:
0.12
Market Cap:
$1.42M
Revenue:
Net Income/Loss:
$-4.23M
P/E Ratio:
-0.0682
EPS:
-8.8
Net Cash Flow:
$-1.89M
1W Performance:
-24.23%
1M Performance:
-72.35%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.581
$0.6276
1-Week Range:
$0.621
$0.8211
52-Week Range:
$0.581
$98.20
Lakewood Amedex Biotherapeutics Inc Stock (LABT) Company Profile
Name
Lakewood Amedex Biotherapeutics Inc
Sector
Industry
Phone
(941) 225-2515
Address
8031 COOPER CREEK BLVD., UNIVERSITY PARK
Compare LABT vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LABT
Lakewood Amedex Biotherapeutics Inc
|
0.6001 | 1.42M | 0 | -4.23M | -1.89M | -8.80 |
VRTX
Vertex Pharmaceuticals Inc
|
508.43 | 128.87B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.56 | 94.84B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.54 | 82.42B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
849.87 | 53.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.60 | 42.04B | 5.76B | 514.49M | 1.10B | 4.4813 |
Lakewood Amedex Biotherapeutics Inc Stock (LABT) Latest News
Lakewood-Amedex Biotherapeutics Inc.Common Stock (Nasdaq:LABT) Stock Quote - FinancialContent
LABT Stock Whipsaws As Traders Focus On Cash And Volatility - Timothy Sykes
A topical candidate showed lab activity against drug-resistant bacteria from foot ulcers - Stock Titan
Is Lakewood-Amedex Biotherapeutics Inc. (LABT) Rewriting the Penny Stocks Playbook? - Kalkine Media
Lakewood-Amedex Biotherapeutics (LABT) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
How Is Lakewood-Amedex (NASDAQ:LABT) Preparing Its Nu-3 Program for Midstage Testing? - Kalkine Media
Lakewood-Amedex Biotherapeutics CEO Issues Shareholder Letter Highlighting Transformational Progress & Outlook for Nu-3 - The Columbus Dispatch
Lakewood-Amedex Biotherapeutics CEO Issues Shareholder Letter Highlighting Transformational Progress & Outlook for Nu-3 - Akron Beacon Journal
Lakewood-Amedex CEO outlines progress, Phase 2a trial ahead By Investing.com - Investing.com Canada
Before human trials, a wound gel killed drug-resistant bacteria without generating resistance - Stock Titan
Lakewood-Amedex CEO outlines progress, Phase 2a trial ahead By Investing.com - Investing.com Australia
Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3 - PR Newswire
Lakewood-Amedex CEO outlines progress, Phase 2a trial ahead - Investing.com
IPO Databook: Lakewood-Amedex Biotherapeutics (LABT US)Sep 2026 - Smartkarma
LABT Price Today: Lakewood-Amedex Biotherapeutics Inc. Stock Price, Quote & Chart | MEXC - MEXC
Lakewood-Amedex (NASDAQ: LABT) faces shareholder stock resale that brings it no cash - Stock Titan
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - openPR.com
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - Akron Beacon Journal
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - Democrat and Chronicle
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - azcentral.com and The Arizona Republic
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - Kitsap Sun
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - The Tennessean
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - The National Law Review
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - WBOC TV
Lakewood-Amedex CEO to present new antimicrobia... - Pluang
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - PR Newswire
Investors and potential partners will meet a biotech CEO from Lakewood-Amedex Sept. 14–16 - Stock Titan
Biotech Pre-Market Movers: BIAF, LABT, ALMS, PASW Swing Big - RTTNews
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Trending Stocks Today | SONO Group Soars 81.34% Post-Market - Moomoo
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Lakewood-Amedex Biotherapeutics Company Profile & Introduction - Moomoo
Lakewood-Amedex Biotherapeutics Becomes a B2i Digital Featured Company - markets.businessinsider.com
Lakewood-Amedex Biotherapeutics Becomes a B2i Digital Featured Company - Yahoo Finance
Lakewood-Amedex Biotherapeutics Inc. Common Stock (NASDAQ: LABT) Stock Price, News & Analysis - Kalkine
Lakewood-Amedex Biotherapeutics Inc. Common Stock (NASDAQ: LABT) Stock Price, News & Analysis - kalkine.ca
Lakewood-Amedex Biotherapeutics (LABT) investor WFI Equity discloses 8.8% ownership stake - Stock Titan
Lakewood-Amedex raises $7.5M Series C, lists on Nasdaq and clears $1.5M debt - Dealroom
Lakewood-Amedex Raises $7.5M and Lists on NASDAQ, Shedding $1.5M Debt - Minichart
LABT: Q2 net loss rose sharply on higher R&D and G&A costs; liquidity improved after Series C financing - TradingView
Lakewood-Amedex Biotherapeutics Inc. Q2 2026: Revenue $0 Net loss $(3.90M), EPS $(2.75) — 10-Q Summary - TradingView
Lakewood-Amedex (NASDAQ: LABT) raises $7.5M, expands cash yet flags going concern - Stock Titan
Upcoming and recent IPOs – IPOs calendar - Yahoo Finance Australia
Lakewood-Amedex Biotherapeutics announces annual shareholder meeting - Bitget
Lakewood-Amedex Biotherapeutics announces annual shareholder meeting - Bitget
Lakewood-Amedex (NASDAQ: LABT) seeks 100M share authorization and reverse split power - Stock Titan
Lindesfarne LLC reports 8.582% LABT stake in Lakewood-Amedex Biotherapeutics (LABT) filing - Stock Titan
Lakewood-Amedex Biotherapeutics (LABT) Earnings Date and Reports 2026 $LABT - MarketBeat
Lakewood-Amedex Biotherapeutics (LABT) asks investors to approve major share and reverse split powers - Stock Titan
Lakewood-Amedex Biotherapeutics Inc. Revenue Breakdown – NASDAQ:LABT - TradingView
Lakewood Amedex Biotherapeutics Inc Stock (LABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):